Osteoporosis - secondary prevention including strontium ranelate: appeal letter to consultees and commentators
The clinical effectiveness and cost effectiveness of technologies for the primary prevention of osteoporotic fragility fractures in postmenopausal women AND Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women Appeal
The Institute has received four appeals against the Final Appraisal Determination and Guidance on this technology. The appeal hearing is currently being arranged.
As set out in the Guidance for Appellants members of the public, including consultees and commentators for this appraisal, and the press, may request to attend the hearing. The number of observers admitted to the hearing will be limited to a number appropriate for the venue, and priority will be given to members of the public who are not employed by the appellants. Details of the hearing and how to register to attend will be posted on this page when they have been finalised. The Institute will not accept early requests to attend.
The names of the appellants will be published on this page on the day of the appeal. The Institute will not comment on speculation as to the identity of appellants prior to publication of this information on the Institute’s website.
This page was last updated: 30 March 2010